New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
PolyPid Ltd. announced a new research and development collaboration with ImmunoGenesis Inc. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes agonist drug candidate to potentially enhance treatment for solid tumors.
Robert Schnoll, Penn Medicine’s Abramson Cancer Center’s associate director for population science, was named the John H. Glick, MD Professor in Cancer Research. Schnoll is also the director of the Center for Interdisciplinary Research on Nicotine Addiction, a senior fellow in the Penn Center for Public Health, and co-director of the Community Research and Engagement Core at the Penn Center for AIDS Research.
Exact Sciences Corp. presented three abstracts highlighting advancements in the development of a multi-cancer early detection test at the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy from Nov. 13-16, in San Diego, CA.
Melissa L. Fishel was named the Myles Brand Scholar in Cancer Research by Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Fishel is a tumor cell biologist working toward new targets and treatments for pancreatic cancer.
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting.
UChicago Medicine received a $75 million donation from the AbbVie Foundation, a nonprofit focused on advancing health equity, to help fund the construction of the new cancer care and research pavilion.
Together for Supportive Cancer Care, a national coalition that will work to expand early, equitable access to whole-person, supportive care for all people with cancer, regardless of where they receive care, has launched.
LSU LCMC Health Cancer Center and Cancer Crusaders have committed $500,000 for state-wide outreach, education, and clinical cancer research.
Coast 2 Coast 4 Cancer has raised more than $1.3 million for cancer research. These funds, which include a $500,000 match from Bristol Myers Squibb, will benefit cancer research at research institutions across North America.
